New appointment at Xention

Dr Patrick Round has been named chief medical officer and head of development at Xention, a UK biopharmaceutical company discovering and developing ion channel-modulating drugs. Dr Round has worked as senior vice-president at Cambridge Antibody Technology, director of development at Celltech R&D, director of clinical development at Glaxo Wellcome, clinical project manager at Novo Nordisk Pharmaceuticals and chief medical officer at Phoqus Pharmaceuticals.

Dr Patrick Round has been named chief medical officer and head of development at Xention, a UK biopharmaceutical company discovering and developing ion channel-modulating drugs. Dr Round has worked as senior vice-president at Cambridge Antibody Technology, director of development at Celltech R&D, director of clinical development at Glaxo Wellcome, clinical project manager at Novo Nordisk Pharmaceuticals and chief medical officer at Phoqus Pharmaceuticals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.